10
May
2010
|
17:25
Europe/Amsterdam

Kuehne + Nagel to transport temperature-controlled shipments for Boehringer Ingelheim to Eastern Europe

Boehringer Ingelheim Pharma Ltd., one of the world’s leading and most innovative pharmaceutical companies, has chosen Kuehne + Nagel for the management of its temperature-controlled transports in five East European countries.

The services Kuehne + Nagel will provide for Boehringer Ingelheim include temperature-controlled road transportation of thermolabile medical products to the Czech Republic, Poland, Hungary, Greece and Croatia. Kuehne + Nagel’s cool-chain transport solution, which is adapted to the sensitive products’ specific nature, meets all relevant industry-specific regulations and the customer’s high quality requirements regard­ing handling, storage and distribution. In order to provide complete tracing of constant temperature, Kuehne + Nagel offers a dedicated control and reporting system.

“As one of the leading pharmaceutical companies we need a logistics service provider who combines thorough industry know-how with experi­ence in the East European market,” says Martina Brzjchaczek-Koternetz, Head of Supply Chain Management at Boehringer Ingelheim. “Kuehne + Nagel is the partner of choice to accompany us on our course for growth.”

Bernhard Schilling, Director Business Development Pharma & Healthcare at Kuehne + Nagel, says: “In recent years we have specifically invested in our systems, facilities and employees in order to guarantee our high service and quality standards for the transport of thermolabile products. To have been chosen by Boehringer Ingelheim as their logistics partner for these five Eastern European countries is proof of the success of our efforts. This important cooperation confirms Kuehne + Nagel’s strategy to invest further into specialised products and grow particularly in market segments such as Pharma & Healthcare and High-Tech / High-Value.”


About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 138 affiliates in 47 countries and 41,300 employees. Since it was founded in 1885, the independent, family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine. For further information, please visit
www.boehringer-ingelheim.com